Senores Pharmaceuticals Limited
Senores Pharmaceuticals issued 11.7 lakh convertible equity warrants via a preferential issue on March 28, 2026, to promoter and promoter group members. The company also appointed Jatin Gajjar as CTO and noted the resignation of President R&D Manohar Lalge.
Apr 07 2026 17:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals, Inc. (SPI), a subsidiary of Senores Pharmaceuticals Limited, has formed a strategic joint venture named Amerisyn, LLC, in the United States. This JV will supply high-quality pharmaceutical products to the U.S. Federal Government and defense sector, marking a significant entry into a high-entry-barrier market.
Apr 03 2026 20:04:00
Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Senores Pharmaceuticals announced a strategic joint venture, Amerisyn, LLC, in the United States. This JV will target U.S. Federal and Defense sector supplies, marking a key entry into government procurement.
Apr 03 2026 20:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' wholly owned subsidiary, Senores Pharmaceuticals Inc., acquired a 70% membership interest in Amerisyn, LLC. This strategic acquisition establishes Amerisyn, LLC, a pharmaceuticals company incorporated on March 5, 2026, as a step-down subsidiary in the USA, expanding the company's global footprint.
Apr 03 2026 19:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' wholly owned subsidiary, Senores Pharmaceuticals, Inc., USA, formed a joint venture named Amerisyn, LLC. The subsidiary subscribed to a 70% membership interest, making Amerisyn a step-down subsidiary focused on pharmaceuticals in North Carolina.
Apr 03 2026 19:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' promoter and promoter group received an allotment of 11.7 lakh convertible equity warrants on a preferential basis. This allotment increases their diluted shareholding to 47.16% of the company's total diluted share capital.
Apr 02 2026 18:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' promoter and promoter group received an allotment of 11.7 lakh convertible equity warrants on a preferential basis. This allotment increases their diluted shareholding to 47.16% of the company's total diluted share capital.
Apr 02 2026 18:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' promoter and promoter group received an allotment of 11.7 lakh convertible equity warrants on a preferential basis. This allotment increases their diluted shareholding to 47.16% of the company's total diluted share capital.
Apr 02 2026 18:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' promoter and promoter group received an allotment of 11.7 lakh convertible equity warrants on a preferential basis. This allotment increases their diluted shareholding to 47.16% of the company's total diluted share capital.
Apr 02 2026 18:04:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals' promoter and promoter group received an allotment of 11.7 lakh convertible equity warrants on a preferential basis. This allotment increases their diluted shareholding to 47.16% of the company's total diluted share capital.
Apr 02 2026 18:04:00
Read More
